title: Pharmacological aspects of the safety of gliflozins.
abstract: Sodium-glucose transporter 2 (SGLT2) inhibitors, also known as gliflozins, are a new class of orally active drugs used in the management of type 2 diabetes. By inhibiting the SGLT responsible for the reabsorption of glucose from the kidney, their use aims primarily to induce glycosuria and, as a consequence, lower glycemic levels. However, their specific mechanism of action involves other pharmacodynamic consequences including potentially harmful adverse reactions. This manuscript reviews the physiological and pharmacological background behind inhibition of SGLTs, and discusses the pharmacological aspects of the safety of gliflozins.
authors.affiliation: Department of Medical Pharmacology and Toxicology, CHU Montpellier University Hospital, Montpellier, France; Laboratory of Biostatistics, Epidemiology and Public Health (EA 2415), Faculty of Medicine, University of Montpellier, Montpellier, France. Electronic address: jean-luc.faillie@umontpellier.fr.
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Faillie
mesh_terms: D000818:Animals; D001559:Benzhydryl Compounds / Q000009:adverse effects* / Q000493:pharmacokinetics; D050723:Fractures, Bone / Q000139:chemically induced; D005919:Glomerular Filtration Rate / Q000187:drug effects; D005960:Glucosides / Q000009:adverse effects* / Q000493:pharmacokinetics; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007662:Ketosis / Q000139:chemically induced; D008055:Lipids / Q000097:blood; D051269:Sodium-Glucose Transporter 1 / Q000037:antagonists & inhibitors; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; D008055:Lipids; D051269:Sodium-Glucose Transporter 1; D000077203:Sodium-Glucose Transporter 2 Inhibitors; C529054:dapagliflozin
keywords: Adverse reactions; Canagliflozin (PubChem CID: 24812758); Dapagliflozin (PubChem CID: 9887712); Drug safety; Empagliflozin (PubChem CID: 11949646); Ipragliflozin (PubChem CID: 10453870); Phlorizin(PubChem CID: 6072); SGLT2 inhibitors; Sodium-glucose transporters; Tofogliflozin (PubChem CID: 46908929); Type 2 diabetes